应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01801 信达生物
午间休市 04-16 12:05:00
91.850
+0.450
+0.49%
最高
92.400
最低
89.450
成交量
524.87万
今开
91.400
昨收
91.400
日振幅
3.23%
总市值
1,594亿
流通市值
1,594亿
总股本
17.35亿
成交额
4.78亿
换手率
0.30%
流通股本
17.35亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
港股收盘丨恒指涨0.29% 老铺黄金涨近7%
第一财经 · 04-15 16:12
港股收盘丨恒指涨0.29% 老铺黄金涨近7%
信达生物在上海成立医药公司
视频滚动新闻 · 04-15 14:36
信达生物在上海成立医药公司
玛仕度肽副作用突出：信达生物大单品焦虑
财中社 · 04-10
玛仕度肽副作用突出：信达生物大单品焦虑
免疫重塑前沿：信达生物在2026年B细胞介导及超越峰会上公布靶向自身免疫病三特异性T细胞衔接抗体IBI3055临床前研究结果
美股速递 · 04-10
免疫重塑前沿：信达生物在2026年B细胞介导及超越峰会上公布靶向自身免疫病三特异性T细胞衔接抗体IBI3055临床前研究结果
信达生物更新3月股份变动月报表，已发行股本小幅增加
公告速递 · 04-09
信达生物更新3月股份变动月报表，已发行股本小幅增加
对话耀速科技谢鑫：当器官芯片走向商业化，药企为“降低研发不确定性与失败风险”付费
华尔街见闻 · 04-08
对话耀速科技谢鑫：当器官芯片走向商业化，药企为“降低研发不确定性与失败风险”付费
【特约大V】邓声兴：美伊若终战 恒指望二万八
金吾财讯 · 04-08
【特约大V】邓声兴：美伊若终战 恒指望二万八
Ede Ronald Hao Xi减持信达生物(01801)100万股 每股作价约85港元
智通财经 · 04-04
Ede Ronald Hao Xi减持信达生物(01801)100万股 每股作价约85港元
因公出差也能“赚积分当钱花” ，酒店业打开创新新思路｜一克商评
封面新闻 · 04-01
因公出差也能“赚积分当钱花” ，酒店业打开创新新思路｜一克商评
大行评级丨招银国际：微升信达生物目标价至113.86港元，维持“买入”评级
中金财经 · 03-31
大行评级丨招银国际：微升信达生物目标价至113.86港元，维持“买入”评级
信达生物(01801)授出193.56万份购股权及1024.13万股受限制股份
智通财经 · 03-31
信达生物(01801)授出193.56万份购股权及1024.13万股受限制股份
信达生物合作伙伴奥霖生物公布Ibi324对比法瑞西单抗（Vabysmo）治疗湿性年龄相关性黄斑变性与糖尿病黄斑水肿头对头随机研究的最终数据
美股速递 · 03-31
信达生物合作伙伴奥霖生物公布Ibi324对比法瑞西单抗（Vabysmo）治疗湿性年龄相关性黄斑变性与糖尿病黄斑水肿头对头随机研究的最终数据
中金：维持信达生物(01801)跑赢行业评级 目标价118.3港元
智通财经 · 03-30
中金：维持信达生物(01801)跑赢行业评级 目标价118.3港元
信达生物首现年度盈利：创新药企“收获期”来临？
21世纪经济报道 · 03-30
信达生物首现年度盈利：创新药企“收获期”来临？
花旗：升信达生物(01801)目标价至115港元 评级“买入”
智通财经网 · 03-27
花旗：升信达生物(01801)目标价至115港元 评级“买入”
港股异动 | 创新药板块午后拉升，昭衍新药涨超13%，石药集团涨超11%
老虎资讯综合 · 03-27
港股异动 | 创新药板块午后拉升，昭衍新药涨超13%，石药集团涨超11%
港股异动丨业绩亮眼，信达生物大涨超7%
中金财经 · 03-27
港股异动丨业绩亮眼，信达生物大涨超7%
5分钟，封死涨停！千亿巨头，彻底引爆！整个板块集体飙升
券商中国 · 03-27
5分钟，封死涨停！千亿巨头，彻底引爆！整个板块集体飙升
港股创新药集体飙升！信达生物首次全面盈利，一度涨超7%，机构：预期差依然存在
券商中国 · 03-27
港股创新药集体飙升！信达生物首次全面盈利，一度涨超7%，机构：预期差依然存在
信达生物早盘涨超5%
每日经济新闻 · 03-27
信达生物早盘涨超5%
加载更多
公司概况
公司名称：
信达生物
所属市场：
SEHK
上市日期：
--
主营业务：
信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":91.85,"timestamp":1776312300003,"preClose":91.4,"halted":0,"volume":5248698,"delay":0,"changeRate":0.0049234135667394815,"floatShares":1735000000,"shares":1735000000,"eps":0.5399973631465602,"marketStatus":"午间休市","change":0.45,"latestTime":"04-16 12:05:00","open":91.4,"high":92.4,"low":89.45,"amount":478480676,"amplitude":0.032276,"askPrice":91.85,"askSize":1000,"bidPrice":91.8,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":0.5399973631465602,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776315600000},"marketStatusCode":3,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":91.4,"openAndCloseTimeList":[[1776303000000,1776312000000],[1776315600000,1776326400000]],"volumeRatio":0.929894,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.114,"impliedVolPercentile":0.0082},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2627404427","title":"港股收盘丨恒指涨0.29% 老铺黄金涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627404427","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627404427?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:12","pubTimestamp":1776240751,"startTime":"0","endTime":"0","summary":"恒生指数收涨0.29%，恒生科技指数涨1.23%。老铺黄金涨近7%，信达生物、中国生物制药涨逾5%，京东集团涨逾4%，阿里巴巴、携程集团、百度集团涨逾3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705909775.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705909775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SBHMY","SG9999001051.SGD","01177","513600","BK4588","SGXZ90724238.SGD","BK1227","01801","JD","09988","09618","09961","BABA","TCOM","BK1544","MHImain","HSI","HSTECH","02833","MCHmain","BK4585","HHImain","06181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627050734","title":"信达生物在上海成立医药公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2627050734","media":"视频滚动新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627050734?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:36","pubTimestamp":1776234960,"startTime":"0","endTime":"0","summary":"企查查APP显示，近日，上海众煦嘉和医药有限公司成立，法定代表人为关战旗，经营范围包含：药品零售；药品进出口；国内货物运输代理；食品销售（仅销售预包装食品）；保健食品（预包装）销售等。企查查股权穿透显示，该公司由信达生物间接全资持股。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/videoroll/2026-04-15/doc-inhuqfuy0878477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2097828805.USD","BK1589","LU2097828474.EUR","01801","BK1161","LU0502904849.HKD","LU2097828557.USD","LU2097828714.EUR","LU2488822045.USD","LU1969619763.USD","LU0455707207.USD","LU2097828631.EUR","LU2328871848.SGD","BK1583","HK0000165453.HKD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626619271","title":"玛仕度肽副作用突出：信达生物大单品焦虑","url":"https://stock-news.laohu8.com/highlight/detail?id=2626619271","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626619271?lang=zh_cn&edition=full","pubTime":"2026-04-10 19:53","pubTimestamp":1775821980,"startTime":"0","endTime":"0","summary":"从第一款产品上市到收入突破100亿元，信达生物（01801.HK）仅用七年。2025年，这家国产创新药企交出了一份令市场瞩目的成绩单：营收130.41亿元，同比增长38.4%；首次实现全年IFRS净利润8.14亿元，Non-IFRS净利润达17.23亿元，同比增长419.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701449382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU0502904849.HKD","LU2097828714.EUR","HK0000165453.HKD","BK1583","01801","LU2097828631.EUR","LU2328871848.SGD","LU2097828805.USD","LU1969619763.USD","LU2242644610.SGD","LU2488822045.USD","LU2097828474.EUR","LU0455707207.USD","BK1589","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171811132","title":"免疫重塑前沿：信达生物在2026年B细胞介导及超越峰会上公布靶向自身免疫病三特异性T细胞衔接抗体IBI3055临床前研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1171811132","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171811132?lang=zh_cn&edition=full","pubTime":"2026-04-10 08:01","pubTimestamp":1775779275,"startTime":"0","endTime":"0","summary":"在2026年\"免疫重塑：B细胞介导及超越\"峰会的一场重要口头报告中，信达生物公布了其创新药物IBI3055的临床前研究数据。IBI3055是一种靶向自身免疫性疾病的三特异性T细胞衔接抗体，此次公布的临床前结果展现了其在治疗领域的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242644610.SGD","LU2097828714.EUR","LU2488822045.USD","BK1161","01801","LU0455707207.USD","LU2097828557.USD","BK1589","LU0502904849.HKD","LU2097828631.EUR","BK1583","HK0000165453.HKD","LU1969619763.USD","LU2097828805.USD","LU2328871848.SGD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166078317","title":"信达生物更新3月股份变动月报表，已发行股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1166078317","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166078317?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:56","pubTimestamp":1775728574,"startTime":"0","endTime":"0","summary":"信达生物于2026年4月9日披露截至2026年3月31日的股份变动月报表。公告显示，公司法定股本数上月底与本月底均为5,000,000,000股，面值为每股0.00001美元，总计50,000美元，无增减变化。期权与激励计划方面，报告期内主要来自“首次公开发售前股份奖励计划”的期权行使，涉及5,000股新股；“首次公开发售后员工持股计划”“2024年股份计划”等未导致已发行股份数量变化。总计在报告期内新增发行5,000股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625494984","title":"对话耀速科技谢鑫：当器官芯片走向商业化，药企为“降低研发不确定性与失败风险”付费","url":"https://stock-news.laohu8.com/highlight/detail?id=2625494984","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625494984?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:39","pubTimestamp":1775648340,"startTime":"0","endTime":"0","summary":"Xellar正是这份名单中唯一入选的中国器官芯片公司。正是在这样的背景下，耀速科技等器官芯片公司加入了这场产业端的实战大考。2025年6月，FDA牵头启动耀速科技在内的全球9家器官芯片平台的药物诱导性肝损伤联合验证。作为这份名单中的唯一一家中国企业，耀速科技的核心业务正是依托“器官芯片+AI”底层平台，围绕特定疾病模型或研发痛点，与全球药企开展平台驱动的联合研发。比如部分全球药企在完成初期项目后，不再仅仅将器官芯片作为“","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-08/doc-inhtuyvy1466684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4535","BK4585","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625921993","title":"【特约大V】邓声兴：美伊若终战 恒指望二万八","url":"https://stock-news.laohu8.com/highlight/detail?id=2625921993","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625921993?lang=zh_cn&edition=full","pubTime":"2026-04-08 09:40","pubTimestamp":1775612419,"startTime":"0","endTime":"0","summary":"大市全日成交2436亿元。国指跌47点或0.56%，报8456点；科指跌77点或1.63%，报4679点。燃料成本上涨忧虑下，联合航空股价下滑1.8%，达美航空跌1.7%。美伊若终战，恒指望二万八。尤为瞩目的是，集团与武田制药达成多项管线的全球战略合作，巨额首付款将于未来数年逐步确认，为中长期增长注入强劲动力。随着玛仕度肽等重磅新品快速成长为基石品种，商业化产品组合迅速扩大。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/MTBhNmJhMjNhYmJjNDg2MTczNjQ3NDEwNzUzMg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MTBhNmJhMjNhYmJjNDg2MTczNjQ3NDEwNzUzMg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978352","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVS.SI","BK1610","BK1539","BK1583","IE00BZ08YS42.EUR","LU2242644610.SGD","SG9999002828.SGD","01801","IE00B0JY6N72.USD","HSTECH","LU0455707207.USD","LU1969619763.USD","BK1614","LU0502904849.HKD","LU2097828631.EUR","LU0293314216.USD","BK1589","BK1163","LU1224444064.USD","02833","LU1282651121.HKD","BK1164","LU0315179316.USD","HK0000165453.HKD","IE00BZ08YT58.USD","LU1861214812.USD","LU2097828557.USD","LU2488822045.USD","IE00BZ08YR35.GBP","GELYY","513600","LU2328871848.SGD","BK1521","LU2097828714.EUR","LU2097828474.EUR","HSI","LU1282651048.USD","LU2097828805.USD","LU2360107325.USD","HHImain","LU1861219969.SGD","BK1119","80175","BK1161","BK1526","BK1607","MCHmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624697162","title":"Ede Ronald Hao Xi减持信达生物(01801)100万股 每股作价约85港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624697162","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624697162?lang=zh_cn&edition=full","pubTime":"2026-04-04 19:22","pubTimestamp":1775301721,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，3月30日，Ede Ronald Hao Xi减持信达生物(01801)100万股，每股作价85.0005港元，总金额为8500.05万港元。减持后最新持股数目约为733.2万股，最新持股比例为0.42%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","LU2097828557.USD","LU2097828805.USD","LU2328871848.SGD","BK1589","HK0000165453.HKD","BK1161","01801","LU2097828631.EUR","LU1969619763.USD","LU2242644610.SGD","LU2488822045.USD","LU2097828714.EUR","LU2097828474.EUR","BK1583","LU0455707207.USD","LU0502904849.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624947535","title":"因公出差也能“赚积分当钱花” ，酒店业打开创新新思路｜一克商评","url":"https://stock-news.laohu8.com/highlight/detail?id=2624947535","media":"封面新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624947535?lang=zh_cn&edition=full","pubTime":"2026-04-01 18:09","pubTimestamp":1775038140,"startTime":"0","endTime":"0","summary":"封面新闻记者张越熙付文超锦江酒店全面升级企业会员积分权益，加码直销构建大会员生态因公出差住酒店，还能“赚积分当钱花”。锦江酒店（中国区）将企业会员积分直接打通个人账号并拓展使用场景，是酒店行业在会员体系竞争中的关键创新。雅迪4月1日起全品类涨价300元以上媒体从雅迪经销商处确认，雅迪决定自2026年4月1日零时起，对全品类产品出厂价格统一调整，单台上调幅度300元以上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-01/doc-inhsywsw1715288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2347655073.USD","LU2191332357.HKD","LU2213496289.HKD","LU0077335932.USD","LU0082616367.USD","LU1037948541.HKD","LU0528227936.USD","LU0210528500.USD","LU0724617625.USD","BK4571","LU0314106906.USD","LU0823434740.USD","LU1720051017.SGD","LU0979878070.USD","LU2471134879.HKD","LU0109391861.USD","LU1244550494.USD","LU1145028129.USD","LU0096364046.USD","SG9999001424.SGD","LU1084165304.USD","LU0965508806.USD","BK4574","SG9999015341.SGD","IE00BLSP4452.SGD","LU1823568750.SGD","LU0788109477.HKD","LU0348723411.USD","IE00BBT3K403.USD","BK4170","GB00BDT5M118.USD","AAPX","LU2237443465.HKD","LU2462157665.USD","LU2125154778.USD","LU2077746001.SGD","LU2456880835.USD","LU0124676726.USD","LU0210533765.USD","IE00BJLML261.HKD","SG9999014567.USD","IE0034235295.USD","LU2065169927.USD","LU1815333072.USD","LU0949170772.SGD","LU0957808578.USD","LU2543165471.USD","LU1267930730.SGD","LU0081259029.USD","LU1868836591.USD","LU2242649171.HKD","BK4566","LU0942090050.USD","LU0820561909.HKD","IE00BN29S564.USD","LU0795875169.SGD","LU2023251221.USD","IE0034235303.USD","LU2896262040.SGD","LU2430703095.HKD","HK0000914686.HKD","LU2271345857.HKD","IE0001KFT4U8.USD","LU2065171402.SGD","IE00B1XK9C88.USD","LU0011850046.USD","LU1291159041.SGD","SG9999000418.SGD","LU0964807845.USD","IE00B5949003.HKD","LU1814569148.SGD","LU1235294995.USD","IE0004445239.USD","LU1035775433.USD","LU0316494557.USD","LU1934455277.USD","LU1989771016.USD","LU2403377893.USD","LU0912757837.SGD","BK4505","LU1242518931.SGD","LU2237443622.USD","SG9999015978.USD","LU1778281490.HKD","LU1642822529.SGD","LU0965509010.AUD","AAPW","LU0157215616.USD","LU2065171311.SGD","SG9999014542.SGD","SG9999015986.USD","BK4533","LU0784385170.HKD","SG9999002224.SGD","LU2168564495.EUR","IE00BZ1G4Q59.USD","BK4585","BK4592","LU0345770308.USD","BK4515","LU0689626769.HKD","LU1815336760.USD","LU1732800096.USD","LU2092627202.USD","IE000KEQY171.SGD","APLY","LU0965509101.SGD","LU1366333091.USD","LU0820562030.AUD","LU0053666078.USD","LU0545039389.USD","LU0784385840.USD","LU0823421333.USD","HK0000320264.USD","LU2106854487.HKD","LU2237443549.SGD","LU0354030511.USD","IE00B19Z9505.USD","LU1116320737.USD","LU0308772762.SGD","AAPB","LU1261432733.SGD","LU2063271972.USD","LU0234572021.USD","LU0683600562.USD","LU0198837287.USD","SG9999014559.SGD","IE00B19Z8X17.USD","LU0661504455.SGD","IE0005OL40V9.USD","IE00BDCRKT87.USD","LU2417539215.USD","SG9999015952.SGD","IE0004091025.USD","LU1127390331.HKD","LU2250418816.HKD","SGXZ31699556.SGD","LU2108987350.USD","LU1206712785.SGD","LU0289739343.SGD","LU0267386448.USD","LU1852331112.SGD","LU0080751232.USD","BK4532","LU1868837136.USD","LU2602419157.SGD","LU2089283258.USD","LU1366192091.USD","LU2087625088.SGD","LU1301847155.USD","LU0726765562.USD","LU0069063385.USD","IE00B19Z8W00.USD","SG9999014898.SGD","LU2242650005.HKD","LU0158827948.USD","LU1868836914.USD","LU1868837300.USD","IE0009G5SDU7.USD","LU0719512351.SGD","LU1046421795.USD","LU0738911758.USD","LU2361044949.HKD","SG9999014575.USD","LU0472753341.HKD","LU0127658192.USD","LU2125154935.USD","IE00BYXW3230.USD","BK4550","LU1280957306.USD","IE0009356076.USD","LU1232071149.USD","LU2237443382.USD","LU1917777945.USD","LU1506573853.SGD","BK4507","LU0170899867.USD","LU0787776722.HKD","LU1935042215.USD","IE000ITXATA3.USD","IE00B7KXQ091.USD","LU1551013342.USD","SG9999015358.SGD","LU0957791311.USD","IE00BJTD4N35.SGD","LU0096362180.USD","LU1582986359.USD","LU2054465674.USD","LU2750360641.GBP","LU2746668461.USD","LU1989772840.SGD","LU2505996509.AUD","LU0265550359.USD","LU0256863902.USD","LU2023250504.SGD","LU2023250843.SGD","LU0820561818.USD","LU0345770993.USD","BK4576","LU2083900584.USD","LU0823421416.USD","LU1868836757.USD","LU2089284900.SGD","LU1582987597.SGD","IE00B4JS1V06.HKD","LU2247934214.USD","LU0417517546.SGD","LU0203202063.USD","LU0061474960.USD","IE00BK4W5L77.USD","LU0238689110.USD","LU1989764664.SGD","LU0158827781.USD","LU2360106780.USD","LU0353189680.USD","LU1914381329.SGD","LU2420271590.USD","LU1242518857.USD","LU2361045086.USD","LU2087621335.USD","LU0048584097.USD","LU0965509283.SGD","IE00B3S45H60.SGD","LU0553294199.USD","LU2592432038.USD","LU2471134952.CNY","LU2756315664.SGD","LU0057025933.USD","LU0861579265.USD","MACW.SI","LU1066051225.USD","LU0203201768.USD","LU2168564065.EUR","LU0456855351.SGD","LU0882574139.USD","IE00BLSP4239.USD","LU2097344431.USD","SG9999002232.USD","IE0004086264.USD","SG9999014880.SGD","LU0061475181.USD","BK4527","LU2347655156.SGD","LU2756315318.SGD","LU1582987324.SGD","LU1935043023.USD","BK4501","LU2552382058.USD","LU2092937148.SGD","LU2236285917.USD","LU0265550946.USD","LU0079474960.USD","LU1551013425.SGD","IE00BDRTCR15.USD","IE00BK4W5M84.HKD","HK0000320223.HKD","LU0642271901.SGD","LU0109392836.USD","LU2458330243.SGD","LU0320765059.SGD","AAPD","LU0889565833.HKD","LU0251132253.USD","LU0289961442.SGD","LU2111349929.HKD","LU2357305700.SGD","AAPU","LU0345768153.USD","LU1934455194.USD","LU0154236417.USD","LU2552382132.HKD","LU0097036916.USD","LU2133065610.SGD","IE0003U64NQ7.SGD","SG9999018865.SGD","BK4554","LU1791710400.SGD","LU1935043536.SGD","LU1699723380.USD","IE00B775H168.HKD","LU1839511570.USD","LU0823434583.USD","LU1718418525.SGD","LU1571399168.USD","IE00BSNM7G36.USD","LU1674673428.USD","BK4573","LU0795875086.SGD","LU1989764748.USD","LU0784383803.USD","LU2458330169.SGD","IE00BKVL7J92.USD","LU1244550221.USD","BK4553","IE00BKDWB100.SGD","LU1935042991.SGD","LU2023250330.USD","LU1496350171.SGD","IE00BN8TJ469.HKD","LU2065170008.USD","LU0511384066.AUD","LU0689472784.USD","LU1674673691.USD","LU1003077747.HKD","LU1935042488.USD","LU2168563687.JPY","HK0000914660.USD","LU2168564222.USD","LU0072462426.USD","LU2168564149.EUR","LU1066051811.HKD","LU2361044865.SGD","BK4534","IE00BFSS7M15.SGD","IE000YTNTUN2.SGD","LU0345768740.USD","LU1989772923.USD","LU1116320901.HKD","LU0868494617.USD","IE00B775SV38.USD","IE00B3SWFQ91.USD","LU0345769631.USD","LU2430703178.SGD","LU0949170426.SGD","LU0215105999.USD","LU0353189763.USD","LU0056508442.USD","IE00BJJMRY28.SGD","SG9999014906.USD","LU1732799900.SGD","IE00B1BXHZ80.USD","LU0868494708.USD","LU0354030438.USD","IE00BJJMRX11.SGD","LU1066051498.USD","LU1629891620.HKD","LU2237438978.USD","LU2028103732.USD","01801","HK0000306685.HKD","LU0786609619.USD","LU1934455863.HKD","BK4588","LU2360032135.SGD","LU0345769128.USD","LU2860962120.EUR","LU0466842654.USD","LU0256863811.USD","LU1037948897.HKD","IE00BJTD4V19.USD","BK4575","LU2097344357.USD","LU0070217475.USD","LU0708995401.HKD","LU1119994496.HKD","SG9999014914.USD","SG9999015945.SGD","HK0000306701.USD","LU1206713676.USD","LU1548497426.USD","LU2286300806.USD","LU0234570918.USD","LU2750360997.AUD","IE0004445015.USD","01585","LU0444971666.USD","LU2265009873.SGD","LU2505996681.GBP","LU2487616109.SGD","LU2461242641.AUD","AAPY","IE00B4YYXB79.USD","LU0210536198.USD","LU0494093205.USD","LU0640476718.USD","LU1804176565.USD","LU0444973449.USD","BK4559","IE00BFSS8Q28.SGD","LU0314104364.USD","LU1066053197.SGD","SG9999017495.SGD","LU2452424414.USD","LU2430703251.USD","LU0985320562.USD","LU2746668974.SGD","IE000W1ABFV2.USD","BK4581","LU1720051108.HKD","LU0476273544.USD","LU0943347566.SGD","LU0149725797.USD","BK4512","AAPL","LU1316542783.SGD","LU2237443978.SGD","LU0672654240.SGD","BK4579","LU1803068979.SGD","LU1244550577.SGD","LU1974910355.USD","LU2471134796.USD","LU2552382215.SGD","SG9999018857.SGD","LU1791710582.SGD","LU2381873111.SGD","LU2471134523.USD","IE00BWXC8680.SGD","LU0323591593.USD","BK4598","LU1496350502.SGD","LU0784384876.USD","LU2237443895.HKD","LU1069344957.HKD","LU1582986433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623303768","title":"大行评级丨招银国际：微升信达生物目标价至113.86港元，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2623303768","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623303768?lang=zh_cn&edition=full","pubTime":"2026-03-31 14:27","pubTimestamp":1774938422,"startTime":"0","endTime":"0","summary":"招银国际发表研报指，信达生物2025财年业绩强劲，首次录得全年纯利8.34亿元；总收入达130亿元，按年增长38%；产品销售达119亿元，按年增长45%。鉴于信达生物强大的产品线创新能力和全球发展潜力，加速向全球生物制药商转型，维持对其“买入”评级，目标价从110.62港元微升至113.86港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260331/32115442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["EWH","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623378635","title":"信达生物(01801)授出193.56万份购股权及1024.13万股受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2623378635","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623378635?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:19","pubTimestamp":1774916343,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物(01801)发布公告，于2026年3月30日，公司根据2024年股份计划的条款向66名承授人(包括董事)授出193.56万份购股权并 向 1308名承授人授出1024.13万股受限制股份，惟须待承授人接纳。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0502904849.HKD","LU2328871848.SGD","BK1161","HK0000165453.HKD","01801","LU2097828474.EUR","LU2097828805.USD","LU2097828631.EUR","LU2242644610.SGD","LU2097828714.EUR","LU2488822045.USD","LU1969619763.USD","LU0455707207.USD","BK1589","LU2097828557.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196729260","title":"信达生物合作伙伴奥霖生物公布Ibi324对比法瑞西单抗（Vabysmo）治疗湿性年龄相关性黄斑变性与糖尿病黄斑水肿头对头随机研究的最终数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1196729260","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196729260?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:02","pubTimestamp":1774915356,"startTime":"0","endTime":"0","summary":"信达生物制药的合作方奥霖生物科技正式披露了其创新药物Ibi324与罗氏旗下法瑞西单抗（商品名：Vabysmo）在湿性年龄相关性黄斑变性及糖尿病黄斑水肿治疗领域的头对头随机临床试验最终研究结果。该研究采用直接对比的随机设计，旨在评估两种疗法在关键眼科适应症中的相对疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","BK1589","LU2097828474.EUR","01801","BK1161","LU0502904849.HKD","LU2097828557.USD","LU2097828714.EUR","LU2488822045.USD","LU1969619763.USD","LU0455707207.USD","LU2097828631.EUR","LU2328871848.SGD","BK1583","HK0000165453.HKD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623364421","title":"中金：维持信达生物(01801)跑赢行业评级 目标价118.3港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623364421","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623364421?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:28","pubTimestamp":1774834134,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，信达生物公布2025业绩，收入130.4亿元，同比+38.4%，归母净利润8.14亿元，non-IFRS利润17.23亿元，符合该行预期。该行维持跑赢行业评级，基于DCF估值，维持目标价118.3港元不变，较当前股价有38.36%的上行空间。2026年催化重点关注核心国际化管线进展和早研分子惊喜：1)IBI363 潜在的1L数据读出和注册临床开展计划。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623361207","title":"信达生物首现年度盈利：创新药企“收获期”来临？","url":"https://stock-news.laohu8.com/highlight/detail?id=2623361207","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623361207?lang=zh_cn&edition=full","pubTime":"2026-03-30 08:59","pubTimestamp":1774832340,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛3月26日，港股创新药龙头信达生物（01801.HK）交出了年度成绩单。财报数据显示，公司首次实现国际财务报告准则（IFRS）计量下的全年盈利，净利润达8.14亿元。同期，公司总收入突破130亿元大关，达到130.42亿元，同比增长38.4%，其中核心的产品收入达118.96亿元，同比增长44.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603303688163972.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603303688163972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1583","06978","LU0502904849.HKD","LU0455707207.USD","LU2488822045.USD","159992","BK1161","LU2242644610.SGD","LU2097828557.USD","01801","LU2097828805.USD","LU2097828474.EUR","LU1969619763.USD","LU2328871848.SGD","BK1589","LU2097828631.EUR","HK0000165453.HKD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622846819","title":"花旗：升信达生物(01801)目标价至115港元 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2622846819","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622846819?lang=zh_cn&edition=full","pubTime":"2026-03-27 15:50","pubTimestamp":1774597851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，信达生物去年收入同比升38%至130亿元人民币，纯利录得8.34亿元人民币，同比扭亏为盈。管理阶层重申2027年产品销售额为200亿元人民币指引。管理层指出，尽管近期价格调整和竞争加剧，但玛仕度肽销售仍保持良好势头。该行对公司今年和明年收入上调24%及23%，各年每股盈测分别上调33%及5%，其目标价由110港元上调至115港元，维持其评级为“买入”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184490371","title":"港股异动 | 创新药板块午后拉升，昭衍新药涨超13%，石药集团涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184490371","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184490371?lang=zh_cn&edition=full","pubTime":"2026-03-27 13:05","pubTimestamp":1774587950,"startTime":"0","endTime":"0","summary":"信达生物涨超7%，君实生物、诺诚健华涨超6%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9b241a979bfd22b774f426314475f336","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","01093","06127","01877","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622814147","title":"港股异动丨业绩亮眼，信达生物大涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622814147","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622814147?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:17","pubTimestamp":1774585022,"startTime":"0","endTime":"0","summary":"信达生物(1801.HK)盘中拉升涨超7%，报85.55港元。消息面上，公司昨晚公布业绩显示，2025年实现总收入130.415亿元，同比增38.4%；国际财务报告准则(IFRS)净利润8.136亿元，去年亏损9463万元，同比扭亏为盈，为公司首次全年盈利；Non-IFRS净利润17.231亿元，同比增419.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9b241a979bfd22b774f426314475f336","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260327/32103895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2097828714.EUR","BK4585","BK1583","LU0455707207.USD","LU2097828805.USD","BK1589","VXUS","LU2328871848.SGD","LU2097828557.USD","LU2242644610.SGD","LU2097828474.EUR","BK4588","BK1161","LU0502904849.HKD","HK0000165453.HKD","LU2097828631.EUR","LU1969619763.USD","01801","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622581161","title":"5分钟，封死涨停！千亿巨头，彻底引爆！整个板块集体飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622581161","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622581161?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:31","pubTimestamp":1774582260,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 昨天是锂电池，今天轮到创新药。3月27日早盘，创新药概念持续走高，美诺华（维权）开盘后五分钟封死涨停板，科拓生物20CM涨停，万邦德、联环药业、双鹭药业涨停，热景生物、益诺思涨超10%。A股创新药板块大涨3%。 港股方面亦有反应，信达生物首次全面盈利，重磅战略合作加速兑现管线全球价值，该股一度大涨超7%。彻底引爆整个生物医药板块。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9b241a979bfd22b774f426314475f336","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-03-27/doc-inhskwcy5485109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2097828557.USD","06978","BK1574","LU1969619763.USD","LU2097828474.EUR","LU2097828714.EUR","BK1161","LU0455707207.USD","LU2097828805.USD","LU0502904849.HKD","LU2242644610.SGD","LU2328871848.SGD","01801","BK1583","BK1589","HK0000165453.HKD","LU2488822045.USD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622127088","title":"港股创新药集体飙升！信达生物首次全面盈利，一度涨超7%，机构：预期差依然存在","url":"https://stock-news.laohu8.com/highlight/detail?id=2622127088","media":"券商中国","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622127088?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:31","pubTimestamp":1774582260,"startTime":"0","endTime":"0","summary":"今天轮到创新药！昨天是锂电池，今天轮到创新药。3月27日早盘，创新药概念持续走高，美诺华开盘后五分钟封死涨停板，科拓生物20CM涨停，万邦德、联环药业、双鹭药业涨停，热景生物、益诺思涨超10%。A股创新药板块大涨3%。港股方面亦有反应，信达生物首次全面盈利，重磅战略合作加速兑现管线全球价值，该股一度大涨超7%。彻底引爆整个生物医药板块。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202603273686787813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["BK1574","BK1583","06978","VXUS","LU0502904849.HKD","LU0455707207.USD","LU2488822045.USD","159992","BK1161","BK4585","BK4588","LU2242644610.SGD","LU2097828557.USD","01801","LU2097828805.USD","LU2097828474.EUR","LU1969619763.USD","LU2328871848.SGD","BK1589","LU2097828631.EUR","HK0000165453.HKD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622161038","title":"信达生物早盘涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622161038","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622161038?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:10","pubTimestamp":1774577424,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月27日，信达生物(01801.HK)早盘涨超5%，截至发稿，涨5.48%，报83.75港元，成交额4.74亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686706113.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"9b241a979bfd22b774f426314475f336","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686706113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","LU2097828805.USD","HK0000165453.HKD","01801","LU2242644610.SGD","BK1161","BK1589","LU2097828557.USD","LU0455707207.USD","LU1969619763.USD","LU2328871848.SGD","LU2097828714.EUR","LU0502904849.HKD","LU2097828631.EUR","LU2097828474.EUR","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0868},{"period":"3month","weight":0.027},{"period":"6month","weight":0.0524},{"period":"1year","weight":0.8904},{"period":"ytd","weight":0.1987}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.0044},{"period":"3month","weight":-0.0363},{"period":"6month","weight":0.0277},{"period":"1year","weight":0.2087},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.01934},{"month":4,"riseRate":0.75,"avgChangeRate":0.045284},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}